The Defense Department is awarding another $5.8 million to PharmAthene [PIP] for continued development of Protexia, the company's broad spectrum nerve agent prophylaxis. PharmaAthene in Sept. 2006 received a potential $213 million contract from the Army Space and Missile Command for advanced development of Protexia. As a prophylactic Protexia may reduce or eliminate the need for post-exposure therapeutics.
Recommended
Trending
Congress Updates
Build Of At Least 45 MQ-9s By Start Of FY 2029 Required By SASC Bill
Down to an inventory of 135 MQ-9A Reapers due to the loss of two dozen aircraft in strikes on Iran, the Air Force would have to field at least 45 […]
Kaine On Iranian Girls School Strike: “You Can Be Sure We’re Gonna Get The Answer To That One”
Sen. Timothy Kaine (D-Va.), the ranking member of the Senate Armed Services Committee (SASC) seapower panel, pledged on Tuesday that the Senate will get to the bottom of what happened […]
‘Right To Repair’ Reform In SASC’s FY ‘27 NDAA Sets “Government-Purpose Rights’ As Default
The “Right to Repair” provision secured in the Senate Armed Services Committee’s (SASC) version of the next defense policy bill would establish “government-purpose rights” as a default, requiring defense contractors […]
Pentagon May Make ‘Tradeoffs’ For Low-Cost Autonomous Tech Without Reconciliation Funds, CTO Says
The Pentagon’s chief technology officer has said the department may need to make “tradeoffs” on certain capability priorities if Congress doesn’t pass a reconciliation with $350 billion in requested defense […]